NCT03006172
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone Therapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases:
Additional Notes: Must have PIK3CA mutation
Exclusions: Patients with IBC; History of leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03006172